Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study - Summary - MDSpire
Advertisement
Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study
To characterize dynamic changes in B-cell subsets in SLE patients with antiphospholipid antibody positivity treated with telitacicept and to identify baseline predictors of treatment response.
Key Findings:
Higher proportions of double-negative B cells and plasmablasts were found in aPL-positive SLE patients compared to healthy controls (both p < 0.001).
Significant reductions in DN B-cell proportions and plasmablasts were observed during treatment.
65% of patients achieved an SRI-4 response by week 24, with significant improvements in SLEDAI-2K scores, IgG, anti-dsDNA, and 24-h urine protein.
Higher baseline IgG and anti-β2GPI IgG levels were independently associated with SRI-4 response.
Interpretation:
Telitacicept may effectively influence B-cell subsets in aPL-positive SLE patients, potentially by modulating the differentiation and survival of these cells, with specific baseline immunological markers predicting treatment response.
Limitations:
Small sample size of 20 patients may limit generalizability.
Short follow-up duration of 24 weeks may not capture long-term effects.
Conclusion:
Telitacicept appears to be a safe and effective treatment for aPL-positive SLE, with specific baseline immunological markers potentially guiding treatment decisions.
